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ABSTRACT The question of how genetic materials are trafﬁcked in and out of the cell nucleus is a problem of great
importance not only for understanding viral infections but also for advancing gene-delivery technology. Here we demonstrate
a physical technique that allows gene trafﬁcking to be studied at the single-gene level by combining sensitive ﬂuorescence
microscopy with microinjection. As a model system, we investigate the nuclear import of inﬂuenza genes, in the form of
ribonucleoproteins (vRNPs), by imaging single vRNPs in living cells in real time. Our single-particle trajectories show that
vRNPs are transported to the nuclear envelope by diffusion. We have observed heterogeneous interactions between the
vRNPs and nuclear pore complexes with dissociation rate constants spanning two orders of magnitude. Our single-particle
tracking experiments also provided new insights into the regulation mechanisms for the nuclear import of vRNPs: the inﬂuenza
M1 protein, a regulatory protein for the import process, downregulates the nuclear import of vRNPs by inhibiting the interactions
between vRNPs and nuclear pore complexes but has no signiﬁcant effect on the transport properties of vRNPs. We expect this
single-particle tracking approach to ﬁnd broad application in investigations of genetic trafﬁcking.
INTRODUCTION
Nuclear trafﬁcking of genetic material is critical to a variety
of biological processes. For example, many viruses deliver
their genomes to the cell nucleus for replication and
expression (Whittaker et al., 2000). Gene therapy relies on
the delivery of therapeutic genes into the nuclei of host cells.
Only recently have we begun to unravel the molecular
mechanisms underlying the nuclear trafﬁcking of viral genes
(Whittaker et al., 2000). Even less is known about how
synthetic gene-delivery materials help to target foreign genes
into the cell nucleus (Li and Huang, 2000). Therefore, efforts
to combat viral diseases and to improve gene therapy could
both beneﬁt from new experimental techniques for in-
vestigating gene trafﬁcking. Here we demonstrate that single-
particle tracking in living cells (Byassee et al., 2000; Fusco
et al., 2003; Goulian and Simon, 2000; Harms et al., 2001;
Kues et al., 2001; Lakadamyali et al., 2003; Seisenberger
et al., 2001) is a powerful technique to investigate the nuclear
trafﬁcking of genetic material. Speciﬁcally, tracking a single
genetic carrier particle in a living cell can directly identify
interactions between the particle and speciﬁc cellular
machinery. The physical trajectory of a single genetic
particle can provide unambiguous insights into its transport
mechanisms. This technique can also resolve interesting dy-
namics of the nuclear trafﬁcking process that may be ob-
scured in ensemble measurements.
We explore the nuclear trafﬁcking of inﬂuenza viral genes.
Inﬂuenza has been used as a model system for understanding
the cellular entry of viruses. Inﬂuenza viruses enter cells by
receptor-mediated endocytosis and then progresses to late
endosomes where fusion between the viral and endosomal
membrane leads to the release of viral genes (Klasse et al.,
1998; Lamb and Krug, 2001; Martin and Helenius, 1991b;
Matlin et al., 1981; Skehel and Wiley, 2000; White et al.,
1982; Yoshimura and Ohnishi, 1984). These genes, pack-
aged in the form of ribonucleoproteins (vRNPs), are then
imported into the nucleus where they direct viral replication
and expression (Herz et al., 1981; Kemler et al., 1994; Krug
et al., 1989; Lamb and Krug, 2001; Martin and Helenius,
1991a,b).
The inﬂuenza genome consists of eight segmented RNAs,
ranging from 890 to 2341 nucleotides in length (Lamb and
Krug, 2001; McGeoch et al., 1976). Each single-stranded
RNA is wrapped around multiple copies of the inﬂuenza
nucleoprotein, with approximately one nucleoprotein for
every 24 nucleotides of RNA (Compans et al., 1972; Lamb,
1989; McGeoch et al., 1976; Murti et al., 1988; Ortega et al.,
2000; Pons et al., 1969). The ends of the RNA are bound to
a trimeric polymerase complex that transcribes the RNA both
to make mRNA and to replicate the virus (Herz et al., 1981;
Hsu et al., 1987; Krug et al., 1989). The protein components
of vRNP contain nuclear localization signals to facilitate the
nuclear import of vRNP via nuclear pore complexes (NPCs)
(Bullido et al., 2000; Davey et al., 1985; Jones et al., 1986;
Nieto et al., 1994; O’Neill et al., 1995).
In the early stage of infection, vRNPs are predominantly
imported into the nucleus; in the late stage, progeny vRNPs
assembled in the nucleus are exported from the nucleus, and
the import of vRNPs is inhibited (Bui et al., 1996, 2000;
Kemler et al., 1994; Martin and Helenius, 1991a,b; Neumann
et al., 2000; O’Neill et al., 1998; Whittaker et al., 1996a,b).
The inﬂuenza matrix protein M1 is responsible for down-
regulating the nuclear import of vRNP, whereas both M1 and
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inﬂuenza NS2 play a role in the nuclear export of vRNP (Bui
et al., 1996, 2000; Martin and Helenius, 1991a; Neumann
et al., 2000; O’Neill et al., 1998; Whittaker et al., 1996a,b).
Despite the above advances in understanding the nuclear
import and export of vRNP, several important questions
remain open. Among these is the molecular mechanism
responsible for the transport of vRNPs in the cell. It was
found that actin and microtubule-depolymerizing drugs did
not block the import of vRNPs (Martin and Helenius, 1991b);
however, it remains unknownwhether vRNPs are transported
by active mechanisms or by diffusion in cells with an intact
cytoskeleton. It is also unclear what molecular mechanism is
used by M1 to inhibit the nuclear import of vRNPs.
In this work, we use ﬂuorescence microscopy to track the
behavior of single inﬂuenza vRNP particles in living cells in
real time. This has allowed us to show unambiguously that
vRNPs are transported in the cytoplasm and nucleus by
diffusion. We have also directly observed the interaction
between vRNPs and the nuclear envelope, via NPCs. The
binding between vRNPs and the NPCs is highly hetero-
geneous, with dissociation rate constants ranging from 1 to
100 s. In the late stage of infection when M1 is expressed in
the cell, the interactions between the vRNPs and nuclear
envelope are inhibited signiﬁcantly, but the transport
properties of the vRNPs are nearly identical to that in the
early stage of infection. This suggests that M1 downregulates
the nuclear import of vRNP by directly inhibiting its binding
to the NPCs.
MATERIALS AND METHODS
Reagents
X-31 virus (490715) was purchased from Charles River Laboratories (North
Franklin, CT). A monoclonal antibody to inﬂuenza nucleoprotein (20302)
was purchased from QED Biosciences (San Diego, CA). A monoclonal
antibody to nuclear pore o-linked N-acetylglucosamine (ab2734), RL1, was
purchased from Novus Biologicals (Littleton, CO). The N2 monoclonal
antibody to inﬂuenza hemagglutinin was a gift from Dr. Judith White
(University of Virginia, Charlottesville, VA). Monoclonal antibody to
inﬂuenza M1 was a gift from Dr. Adolfo Garcia-Sastre (Mount Sinai School
of Medicine, New York). Tetramethylrhodamine goat-anti-mouse (T2762)
was purchased from Molecular Probes (Eugene, OR). Wheat germ
agglutinin (L-1020) (WGA) was from Vector Laboratories (Burlingame,
CA). The BS-C-1 cell line (CCL-26) and cell culture media were from
ATCC (Manassas, VA).
Dye labeling of vRNP
Inﬂuenza vRNP was puriﬁed essentially as described previously (Kemler
et al., 1994) with modiﬁcations to facilitate dye labeling. Brieﬂy, inﬂuenza
viruses (1 ml at 2 mg/ml) were pelleted by centrifugation at 35,000 rpm for
40 min at 4C in a Beckman (Fullerton, CA) SW55 Ti rotor. The pellet was
resuspended in disruption buffer of pH 8.1 that contains 100 mMKPO4, 100
mM KCl, 5 mM MgCl2, 5% (w/v) glycerol, 50 mM n-octyl-b-d-
glucopyranoside, 10 mg/ml lysolecithin, and 1.5 mM dithiothreitol (DTT)
at 31C for 35 min. Disrupted virus was loaded onto a glycerol step gradient
(1 ml 70%, 0.75 ml 50%, 0.375 ml 40%, and 1.8 ml 33% (w/v) glycerol in
100 mM KPO4, 150 mM NaCl, pH 7.8) and centrifuged at 45,000 rpm for
4 h at 4C; 300-ml fractions were collected and analyzed on an SDS-PAGE
gel (data not shown). Fractions 11–13 contain puriﬁed vRNPs, consistent
with previous results (Kemler et al., 1994). These fractions were pooled,
diluted in 10 mM KPO4, 120 mM KCl, pH 8.0, pelleted by centrifugation at
45,000 rpm for 2 h at 4C, and then resuspended in 50 ml 10 mMKPO4, and
120 mM KCl, pH 8.0. Puriﬁed vRNPs were then incubated with amine
reactive Cy3 (PA23001; Amersham Biosciences, Piscataway, NJ) in
a carbonate buffer (pH 9.3) with occasional mixing for 1 h at room
temperature. The reaction was quenched with 10 mM Tris and 120 mMKCl,
pH 8.0. Excess dye was removed by three cycles of 1:10 dilution of the
vRNP solution into 10 mM Tris and 120 mM Kcl, pH 8.0, followed by
concentration with a centricon YM-30 concentrator (42410; Millipore,
Chicago, IL). Measurements of the absorption of the dye after each cycle
indicated that this procedure was sufﬁcient to remove the free dye and
additional cycles of puriﬁcation do not further reduce the number of free dye
molecules in the solution. We note that individual free dye molecules were
not detectable under our experimental conditions. The remaining free dyes
in the vRNP solution, if any, did not lead to a noticeable increase in the
ﬂuorescence background of the cell after the injection of vRNP solutions
into the cell. We measured the labeling efﬁciency by ultraviolet-visible (UV-
VIS) absorption spectroscopy and determined that the average number of
dyes per nucleoprotein is one. There are on average 70 nucleoproteins in
each vRNP complex; so each complex was labeled with;70 dye molecules.
After labeling and free dye removal, the vRNPs were analyzed by a second
glycerol step gradient similar to the one used for purifying vRNPs from the
viruses. As determined by SDS-PAGE gel analysis, the dye-labeled vRNPs
appeared at identical fractions in the step gradient as the vRNPs before
labeling, suggesting that there was no signiﬁcant degradation or aggregation
of vRNP during the labeling process.
Cell culture and drug treatment
BS-C-1 cells were maintained in a 5% CO2 environment in Minimum Eagle
Medium (MEM; ATCC) with 10% fetal bovine serum (FBS; ATCC) and
passaged every 2–3 days. For ﬂuorescence imaging, BS-C-1 cells were
cultured in MEM with 10% FBS in petri dishes with glass coverslips on the
bottom. Before ﬂuorescence experiments, cells were washed and incubated
in serum-free and phenol red-free MEM for at least 30 min. Cells are viable
under these conditions; however, they will not replicate in the absence of
FBS. This procedure reduced autoﬂuorescence background due to both
phenol red and FBS. In experiments that test the effect of microtubules on
the transport properties of vRNPs, the cells were incubated for 30 min before
experiments in medium containing 60 mM nocodazole to disrupt micro-
tubules (De Brabander et al., 1976). In experiments that test the effect of
actin, cells were incubated for 30 min before experiments in medium
containing 20 mM cytochalasin D to disrupt actin ﬁlaments (Cooper, 1987).
The drugs were maintained in the cell culture media throughout the
experiments. Disruption of the actin cytoskeleton by 20 mM cytochalasin D
was veriﬁed by ﬁxing treated cells and staining with Alexa Fluor 532
phalloidin (A22282; Molecular Probes). Disruption of microtubules by
60 mM nocodazole was veriﬁed by immunoﬂuorescence with mouse
monoclonal anti-a-tubulin (A11126; Molecular Probes).
Microinjection
Microinjection was done with a homebuilt injector mounted on an Olympus
IX70 inverted microscope (Olympus, Melville, NY) at 37C in serum-free
and phenol red-free MEM. The injector consisted of a Narishigi (hi-7;
Bioscience Tools–CB Consulting, San Diego, CA) needle holder mounted
on a Newport XYZ (460A-XYZ; Newport, Irvine, CA) translation stage.
Regulated, low-pressure compressed air was then applied to back of the
injection needle to create a constant ﬂow of the injection solution out of
the needle. The air pressure applied to the back of the injection needle
was measured with a digital pressure gauge (3834K12; McMaster-Carr,
Chicago, IL).
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For single vRNP tracking experiments, the stock solution of 100 nM
vRNP was typically diluted 1:10 into 10 mM Tris and 120 mM KCl, pH 8.0,
before injection into the cell,. As vRNPs can stick to the glass injection
needle, it is likely that the concentration of vRNP is signiﬁcantly less after
passing through the injection needle. For ensemble experiments that do not
require individual vRNPs to be resolved, the stock vRNP solution was
directly injected into the cell. Movies were taken at least 2 min after injection
to allow labeled vRNP that had leaked from the needle into the extracellular
media to dissipate. Furthermore, as free Cy3 dye is membrane permeable,
this allowed time for any free dye that might contribute to background to
diffuse out of the injected cell.
Epiﬂuorescence and DIC microscopy
The Olympus IX70 microscope was used for both epiﬂuorescence and
differential interference contrast (DIC) illumination. Cy3 dye was excited
with a 532 nm diode-pumped Nd:YAG laser (GCL-025-M; Crystalaser,
Reno, NV). A 545-nm dichroic (545DCLP; Chroma, Brattleboro, VT) was
used to reﬂect the laser line onto the sample. The ﬂuorescent emission was
collected and imaged with a NA ¼ 1.45 603 oil immersion objective
(Olympus). A 550-nm longpass emission ﬁlter (550LP; Chroma) was used
to block scattered laser light and to select for Cy3 emission. A charge-
coupled device (CCD) camera (Coolsnap HQ; Roper Scientiﬁc, Trenton,
NJ) and custom software were used to capture movies at 10 frames per
second (fps), 1 fps, or 0.2 fps. In all cases, the total exposure time for each
frame was 0.1 s. As the Coolsnap is a progressive scan camera, the time to
shift the current frame into the read-out pixels is negligible. The 1-fps and
0.2-fps data were taken by opening a computer-controlled shutter (VMM-D1
and LS6T2; Vincent Associates, Rochester, NY.) in front of the laser, and
synchronized with the camera, for 0.1 s every 1 s or 5 s. All experiments
were conducted at 37C.
Single-particle tracking
To follow the motion of the vRNP, each frame in the movie was ﬁrst
processed by convolution with a Gaussian of width 1.4 pixels and mean
equal to zero. This removed diffuse, low-frequency background signals and
helped to reduce noise in the image. Peaks in the ﬂuorescence image due to
labeled vRNP were detected using an algorithm that ﬁrst searched each
image for pixels of an intensity that was greater than that of their immediate
neighbors. Then, starting at each local maximal pixel, recursion was used to
identify all the pixels belonging to a single peak using the criteria that the
next pixel along the progress direction is of lower intensity then the pixel
under consideration. The intensity of all pixels in the peak was summed to
determine the peak brightness. If the peak brightness was above a threshold,
the local maximum was marked as a potential vRNP peak.
The trajectories of mobile vRNP were then reconstructed in a semi-
automated fashion using the previously identiﬁed peak locations. To study
the transport properties of the vRNP, we analyze only those vRNPs that
could be tracked for at least 20 frames before they disappeared or overlapped
with a second vRNP. After we identiﬁed the ﬁrst frame from which the
vRNP can be tracked, an automated program was used to determine the peak
in the successive frame that is nearest to the peak location in the current
frame to construct the physical trajectory of the vRNP. Mistracking was
manually corrected. A vRNP particle was characterized as mobile if it did
not remain within 0.18 mm (the pixel size) of its current position for more
then two frames.
The trajectories of vRNP bound to the nuclear envelope were determined
in a manner similar to that described above. A vRNP was identiﬁed as being
bound to the nuclear envelope if it met the following criteria: i), the total
distance traveled in ﬁve frames is,0.18 mm (one pixel); ii), it was no more
than 0.5 mm outside or 1.5 mm inside the location of nuclear envelope as
determined by a DIC image of the cell taken immediately before the start of
the ﬂuorescence movies. We note that binding of vRNP in the vicinity of the
nuclear envelope was dramatically reduced in the presence of anti-NPC
antibodies, indicating that these binding events are indeed due to association
of vRNPs with NPCs.
The microscope did not drift by more than 0.2 mm on the timescale of the
longest experiments performed (16 min). In the time course of 16 min,
;60% of the time, the cell morphology would change. It was however still
possible to tell the location of the nuclear envelope to within 1–2 mm. This is
in part due to the discernable differences in the background ﬂuorescence
between the cytoplasm and the nucleus and in part because the vRNP
particles that were ﬁxed in the cell change their positions along with the
morphology change of the cell; thus the positions of these particles allow us
to determine the new position of the nuclear envelope.
Analysis of the motion of ﬁxed vRNPs indicated that the error in our
measurement of the vRNP position was 0.11 mm. As the vRNPs contain on
average 70 dye molecules and thus are relatively bright, cell autoﬂuo-
rescence does not contribute signiﬁcantly to the error in the position
measurements. At the illumination powers used, the cytoplasm of uninjected
cells would give a ﬂuorescence signal comparable to 5–10% of that of a
vRNP and ﬂuorescence from the nucleus was negligible.
Simulation
The simulated vRNP trajectories in two dimensions were generated from
a series of random numbers with a normal distribution. These numbers were
multiplied by a constant factor that was chosen tomatch the average diffusion
coefﬁcient of a real data set. Individual trajectory lengths were randomly
chosen from a uniform distribution with a mean equal to the average data set
length and a width equal to twice the difference between the average data set
length and the shortest trajectory in the data set. The trajectories were
rounded to the nearest pixel to more exactly match the real data.
Immunoﬂuorescence
Immunoﬂuorescence was performed essentially as described previously
(Martin and Helenius, 1991b). Cells were ﬁxed in phosphate buffered saline
(PBS) with 3% formaldehyde for 15 min, neutralized for 15 min in PBS with
50 mM NH4Cl, permeabilized for 6 min in PBS with 0.1% triton, and
blocked for 20 min in PBS with 10% FBS (PBS-FBS). Then they were
incubated for 30 min with the primary antibody in PBS-FBS. After washing
twice using PBS-FBS, they were incubated for another 30 min with the
ﬂuorescent secondary antibody in PBS-FBS. Finally, cells were washed
twice with PBS-FBS before imaging.
RESULTS
To allow imaging of individual inﬂuenza vRNP particles in
living cells, we labeled the vRNPs with Cy3 dyes at the level
of one dye per nucleoprotein. This corresponds to 70 dye
molecules per vRNP on average. Labeled vRNPs were
injected into the cytoplasm of BS-C-1 cells at 37C. After
30 min, the vRNPs were essentially all imported into the
nucleus (Fig. 1, A and B). Both previous data (Kemler et al.,
1994) and ours (not shown) have demonstrated that micro-
injected vRNPs are competent for viral protein expression.
We compared the import kinetics of the Cy3-labeled and
unlabeled vRNPs by injecting cells with the labeled and
unlabeled vRNPs, respectively, and then ﬁxing the cells with
3% formaldehyde at varying times after injection. The
intracellular vRNP distribution of cells injected with labeled
vRNPs was visualized directly by the Cy3 ﬂuorescence,
whereas that of cells injected with the unlabeled vRNPs was
visualized by immunoﬂuorescence with an antinucleoprotein
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antibody. The import kinetics of Cy3-labeled vRNPs was
essentially identical to that of unlabeled vRNPs (Fig. 1C), in-
dicating that dye labeling does not change the kinetics of the
nuclear import process for vRNPs.
It has been shown previously that vRNPs are imported
into the nucleus via NPCs on the nuclear envelope (Kemler
et al., 1994; Martin and Helenius, 1991b). To conﬁrm that
the dye-labeled vRNPs used the same pathway to enter the
nucleus, we coinjected labeled vRNPs with 5 mg/ml WGA
or 2 mg/ml anti-NPC, both of which are known to block
nuclear import via NPCs (Featherstone et al., 1988; Finlay
et al., 1987). In both cases, the nuclear import of labeled
vRNPs was blocked (data shown later), indicating that
labeled vRNPs indeed enter the nucleus via the NPCs.
Next, we explored the transport mechanism of vRNP by
tracking single vRNP particles in living BS-C-1 cells. Low
concentrations of labeled vRNPs were injected into the cells
so that the instantaneous positions of individual vRNP
particles could be tracked (Fig. 2 A and Supplementary
Movie S1). The ﬂat morphology of this cell type helps
tracking of individual vRNPs by keeping them in or near the
focal plane of the microscope. Under typical experimental
conditions, ;60% of the vRNP particles were mobile, and
individual vRNPs could be tracked for ;5 s (50 frames).
To test whether vRNPs are transported by diffusion or by
directed, active transport mechanisms, we determined the
relation between the mean-square distance (ÆDr2æ) traveled
by each mobile vRNP particle and the traveling time (Dt). For
vRNPs both in the cytoplasm and in the nucleus ÆDr2æ
increases linearly with Dt (Fig. 2, B and C), and the velocity
autocorrelation calculated from all the vRNP trajectories
decays to zero in a single step (Fig. 3, A and B). We averaged
the ÆDr2æ versus Dt traces of all mobile vRNP particles in
either the cytoplasm or the nucleus to more carefully check
for anomalous diffusion of the vRNPs. As shown in Fig. 2D,
the average ÆDr2æ is also linear with Dt, further indicating that
the vRNP particles move by diffusion. The slope of the best-
ﬁt line gives an average diffusion coefﬁcient of 0.7 mm2/s in
the cytoplasm.
Electron microscopy indicates that the eight distinct
vRNPs are ;20 nm in diameter and 30–100 nm long
(Compans et al., 1972; Pons et al., 1969). A spherical particle
of diameter 30–60 nm, an object similar in size to a vRNP,
would have a diffusion coefﬁcient of 7 to 15 mm2/s in water.
In the cytoplasm, such a particle would have a diffusion
coefﬁcient ;10–20 times smaller than that in water (Luby-
Phelps, 2000). This means that the expected diffusion co-
efﬁcient would be ;0.3–1.5 mm2/s, very close to what we
observed for vRNP particles.
To further characterize the diffusion properties of vRNPs
in the cytoplasm, we compare our measured distribution of
diffusion coefﬁcients with a simulated distribution (Fig. 3
C). The simulated distribution was derived from a set of
1000 simulated vRNP diffusion trajectories generated using
the average diffusion coefﬁcient obtained from experiments
as the diffusion coefﬁcient. The length of the trajectories in
time was randomly chosen from a range that mimics the
experimental trajectory lengths (see Material and Methods).
As seen in Fig. 3 C, the distribution of diffusion coefﬁcients
is moderately broader then expected from the simulation.
This extra width may be due to the size of distribution of
vRNP particles: the inﬂuenza genome includes eight
FIGURE 1 Nuclear import of dye-labeled vRNP. (A) A DIC image of an
injected cell. (B) A ﬂuorescence image of the same cell, taken 30 min after
vRNP injection, showing nuclear import of the labeled vRNPs. Scale bars:
10 mm. (C) Nuclear import kinetics of labeled and unlabeled vRNPs. The
amount of vRNPs in the cytoplasm and nucleus were quantiﬁed using Cy3
ﬂuorescence and antinucleoprotein immunoﬂuorescence for the labeled and
unlabeled vRNPs, respectively. Fin and Fout indicate, respectively, the
average ﬂuorescence intensities inside and outside the nucleus after
subtraction of a background term determined from areas outside the injected
cells. The t ¼ 0 point indicates the time of injection. The value of Fin/(Fin1
Fout) at t ¼ 0 was determined by coinjecting WGA (5mg/ml) with labeled
vRNP to block import. This value is not zero because vRNPs that are outside
but directly above or below the nucleus contribute to Fin.
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segmented RNA genes, ranging from 890 to 2341
nucleotides in length. Another possible reason for the
additional width may arise from the local differences in the
microenvironment of the cell (Goulian and Simon, 2000;
Kues et al., 2001). We note that the only the vRNPs that can
be tracked for more than 20 frames (2 s) are analyzed, and
such analysis may bias the distribution toward the more
slowly diffusing vRNPs.
In the early stage of infection, incoming vRNPs are
imported and retained in the nucleus. By observing the
trajectories of vRNPs after import into the nucleus, we found
that the movement of vRNP was also diffusive with a
moderately lower diffusion coefﬁcient (Figs. 2, C and D, and
3 D), indicating that the vRNP are not retained in the nucleus
by interactions with ﬁxed nuclear structures.
To further explore the transport properties of vRNPs in
cells, we carried out two control experiments and measured
the transport properties of vRNPs in cells treated with either
a microtubule-disrupting drug (nocodazole) or an actin-
disrupting drug (cytochalasin D). Although these drugs
disrupt the microtubules (De Brabander et al., 1976) or the
actin ﬁlaments (Cooper, 1987; Cooper et al., 1987) and block
the actin- or microtubule-dependent transport of inﬂuenza
viruses inside cells (Lakadamyali et al., 2003), we found that
the transport properties of vRNPs in treated cells was similar
to that in untreated cells and that the nuclear import of
vRNPs was not perturbed by these two drugs (Martin and
Helenius, 1991b). These observations further support the
conclusion that the vRNP are transported primarily by
diffusion in the cytoplasm.
Next, we investigate the interaction of vRNPs with
NPCs. After labeled vRNPs were injected into a cell, a
ﬂuorescent ring was observed around the nucleus before
signiﬁcant import, indicating the preferential binding of the
vRNPs to the nuclear envelope (Fig. 4 A). In a control
experiment, a monoclonal antibody against nuclear pore
o-linked N-acetylglucosamine (RL1) that is known to block
nuclear import (Featherstone et al., 1988) was coinjected
with the vRNPs. Western blots have shown that this
antibody binds to a subset of the protein components of
puriﬁed nuclear pore complexes (Snow et al., 1987). In
addition, immunoﬂuorescence and immunogold electron
microscopy experiments have demonstrated that this
antibody speciﬁcally targets the nuclear pore complex in
ﬁxed cells (Snow et al., 1987). The import of vRNPs was
indeed blocked by the presence of this antibody, and no
ﬂuorescent ring was observed around the nucleus (Fig. 4 B),
suggesting that the binding of vRNPs to the nuclear
envelope was mediated by the NPCs. By contrast, when
WGA, a molecule that is known to only inhibit trans-
location across the NPCs but does not block binding sites
on the NPC (Newmeyer and Forbes, 1988), was coinjected
with the vRNPs, import of vRNPs was again blocked, but
the accumulation of vRNPs at the nuclear envelope was
more pronounced (Fig. 4 C). The above results indicate that
the observed association of the vRNPs with the nuclear
envelope was due to their binding to the NPCs, probably
through karyopherin molecules, the nuclear import factors
that mediate the binding of vRNP to the NPC (O’Neill et al.,
1995).
FIGURE 2 Tracking the movement of single
vRNPs. (A) A DIC image of part of a cell with
the trajectories of two example vRNP particles
overlaid as black lines. Scale bar: 10 mm. (B)
The measured mean-square displacement
(ÆDr2æ) versus time (Dt) for four example
vRNPs in the cytoplasm of a cell. Lines are
the best ﬁt to ÆDr2æ ¼ 4DDt, with D being the
diffusion coefﬁcient. (C) ÆDr2æ versus Dt for
four example vRNPs in the nucleus of a cell.
The vRNP trajectories were determined 15 min
after injection; this allowed the majority of the
vRNPs to import into the nucleus. (D) The
average mean-square displacement for all the
vRNP in the cytoplasm (h) or in the nucleus
(s). The cytoplasm data include 108 vRNP
trajectories from six different cells, and the
nucleus data include 37 vRNP trajectories from
six different cells. The average trajectory was
113 frames long in the cytoplasm and 54
frames long in the nucleus.
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To characterize this interaction quantitatively, we mea-
sured the time that each vRNP molecule spent bound to the
nuclear envelope. Fig. 4 D and Supplementary Movie S1
show that preferential binding of the vRNP at the nuclear
envelope can be observed at the single-vRNP level when
a lower concentration of vRNPs is injected into the cell. The
time distribution of these binding events shows that vRNP
dissociates from the nuclear envelope with dramatically
different time constants. We therefore performed single-
particle tracking experiments at three different time reso-
lutions: 0.1 s, 1 s, and 5 s. Although the high time resolution
data allow us to determine more accurately the smaller
FIGURE 3 Analysis of the motion of single
vRNPs. (A) The velocity autocorrelation of all
the trajectories of vRNP in the cell cytoplasm
(108 total). The autocorrelation was calculated
using the formula
ÆvðtÞvðt1tÞæ¼ 1ðt11 ::1 tnÞ
3+
n
k¼1
+
tk
t¼0
ðvkðtÞvkðt1tÞÞ;
where n is the number of trajectories, tk(k ¼ 1,
2,. . ., n) are the maximal time in each trajectory
minus t, with t and t both in the unit of frames.
(B) The velocity autocorrelation of all trajecto-
ries in the cell nucleus (37 total). (C) The
shaded columns indicate a histogram of the
measured diffusion coefﬁcients of individual
vRNP particles in the cytoplasm normalized so
that the total area under the curve is 1. The
diffusion coefﬁcient, D, was determined using
the relation ÆDr2æ ¼ 4DDt for each individual
vRNP trajectory. The number of trajectories
used is 108. The solid line with circles is
a simulated distribution of diffusion coefﬁ-
cients calculated from 1000 simulated vRNP
trajectories. The simulated trajectories were
generated using the average diffusion coef-
ﬁcient determined from experiments. The length of the simulated trajectories was randomly chosen from a range that mimics the experimental trajectory
lengths (see Material and Methods). (D) The experimental and simulated distribution of diffusion coefﬁcients for vRNPs in the nucleus. The total number of
experimental and simulated trajectories is 37 and 1000, respectively.
FIGURE 4 The interaction of the vRNP with
the nuclear envelope. (A) A ﬂuorescence image
of a cell taken 2 min after injection of labeled
vRNP. The ring at the nuclear envelope
indicates association of vRNPs with the nuclear
envelope. (B) A ﬂuorescence image of a cell
that was coinjected with labeled vRNP and
anti-NPC (RL1). (C) A ﬂuorescence image of
a cell that was coinjected with labeled vRNP
and WGA. (D) Same as A but with a lower
concentration of labeled vRNP to allow the
detection of individual vRNP particles. The
gray line indicates the location of the nuclear
envelope, determined using DIC microscopy.
The image was convolved with a Gaussian
ﬁlter to reduce noise. Scale bars: 10 mm.
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dissociation time constants, laser excitation is much lower in
the lower time resolution experiments and thus allows us to
track the vRNP particles for a longer time, leading to a more
accurate determination of the larger time constants. At each
time resolution, the total number of frames was kept to 200,
corresponding to 20s, 200s, and 1000s data acquisition times
for the three different time resolutions, respectively (see
Materials and Methods for details). Photobleaching is
negligible in 200 frames. At a certain time resolution, only
the dissociation time constants that are much smaller than the
observation time window are trusted with conﬁdence. At all
but the lowest time resolution, the time distribution of these
vRNP binding events cannot be ﬁt well by single exponential
decays but requires at least two time constants to ﬁt the
experimental data. The combination of all three sets of data
appears to indicate the existence of three discrete dissocia-
tion constants: 1 s, 10 s, and 90 s (Fig. 5, A–C). We do not
formally preclude the possibility that vRNPs bind to the
nuclear envelope with a continuous distribution of time
constants. The above results indicate the presence of multiple
types of interactions between the vRNP and the NPC. The
occurrence frequency of the binding events is higher than
that of the nuclear import events of vRNPs, as estimated
from their import kinetics. This result suggests that a vRNP
particle binds to NPCs multiple times before its translocation
through the NPCs. We note that it is difﬁcult to determine
directly whether a binding event leads to nuclear entry by
tracking the vRNP position because a vRNP above or below
the nucleus may appear to be inside the nucleus due to the
depth of focus of the wide-ﬁeld microscope.
Late in infection, the nuclear import of vRNPs is inhibited
to prevent progeny vRNPs from reentering the nucleus, thus
facilitating virus packaging. The protein responsible for this
downregulation is inﬂuenza M1 (Bui et al., 1996, 2000;
Whittaker et al., 1996a). How M1 inhibits the nuclear import
of vRNP is, however, unclear. Several different mechanisms
may be possible: M1 could inhibit the nuclear import of
vRNPs by promoting their interactions with cellular matrices,
thus keeping them away from the nuclear envelope; by
blocking the binding of vRNPs to the NPCs; or alternatively
by preventing the vRNPs bound to NPCs from translocating
through the pore.
To distinguish the above mechanisms, we injected labeled
vRNP into BS-C-1 cells that were preinfected with inﬂuenza
viruses for 6 h. Under this condition, M1 proteins are
expressed in cells, as determined by immunoﬂuorescence
(data not shown), and the nuclear import of vRNPs was
blocked (Fig. 6 A). Tracking of single vRNPs revealed that
they still moved diffusively, as indicated by the linear
dependence of ÆDr2æ on Dt (not shown) and the velocity
autocorrelation function (Fig. 6 B). The diffusion coefﬁcients
were slightly larger than those in the absence of M1 (Fig. 6
C). This shows that M1 does not block import of the vRNP
by promoting the interaction of vRNP with cellular matrices
or inhibiting the mobility of vRNPs.
When labeled vRNPs were injected into cells preinfected
with inﬂuenza, preferential association of vRNPs with the
nuclear envelope was not observed (Fig. 6 A), whereas such
a behavior (the ﬂuorescent ring at the nuclear envelope) was
observed when the same concentration of vRNPs were
injected into uninfected cells (Fig. 4, A and C). This suggests
that preinfection signiﬁcantly inhibits the binding interaction
between the vRNP and the nuclear envelope. In addition, we
performed experiments at the single-vRNP level by injecting
a lower concentration of vRNPs. We found that in movies
taken at 10 fps there were on average 1.3 binding events per
preinfected cell (15 cells total) versus 14 binding events per
uninfected cell (13 cells total). After accounting for the
apparent differences in vRNP concentration in the cell by
counting the average number of vRNP visible in the infected
versus uninfected cells, we determined that the binding
frequency of vRNP to the nuclear envelope is reduced by
fourfold.
These results indicate that in the late stage of infection the
binding of the vRNPs to the nuclear envelope is signiﬁcantly
inhibited. We propose that M1 proteins block the nuclear
localization signals on the vRNP from interacting with
karyopherin molecules, the nuclear import factors that
mediate the binding of vRNP to the NPC (O’Neill et al.,
1995). This effectively blocks the interaction of vRNPs with
NPCs and thus inhibits the nuclear import of the vRNPs.
DISCUSSION
In the course of an inﬂuenza infection, the vRNP enter the
cytoplasm after viral fusion with a late endosomal
compartment. The sites where this fusion occurs are often
at some distance from the nucleus, and thus the mechanism
by which the vRNP are transported in the cytosol is
important for the nuclear import of vRNP. Our single-vRNP
trajectories directly show that inﬂuenza genes are trans-
ported by diffusion, both in the cytoplasm and in the
nucleus. This experiment allowed the transport mechanisms
of vRNPs to be determined without the use of depolymer-
izing drugs that perturb normal cellular functions. The time
trajectories of single vRNPs have also revealed binding
between the vRNPs and the nuclear envelope, with
dissociation rate constants ranging from 0.01 to 1 s1.
Experiments in the presence of anti-NPC and WGA indicate
that these binding events are due to vRNP-NPC interac-
tions, likely mediated by nuclear import factors. We found
that the binding of vRNPs to NPCs in the late stage of
infection was inhibited in comparison to the early infection
stage, but that the transport properties of vRNPs are almost
identical in both stages. These results suggest that M1,
expressed in the late stage of infection, inhibits the nuclear
import of vRNPs by directly blocking their interactions with
NPCs. M1 may block the vRNP-NPC interaction by
blocking the nuclear localization signals on the vRNP,
preventing their interaction with the nuclear import factors
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that mediate the binding of vRNP to the NPC (O’Neill et al.,
1995).
Our experiments have shown that the behavior of single
viral genes can be tracked in living cells. We expect this
single-particle tracking approach to have many applications
FIGURE 6 vRNP transport and vRNP-NPC interaction during the late
stage of infection. (A) A ﬂuorescence image of a cell taken 10 min after
injection with labeled vRNPs. The cell was infected with inﬂuenza viruses
6 h before injection. No ﬂuorescent ring is observed at the nuclear envelope
in contrast to Fig. 3 A. (B) The velocity autocorrelation of all the vRNP
trajectories in the cytoplasm of preinfected cells (163 trajectories and 17
cells). (C) The distribution of diffusion coefﬁcients, D, in the cytoplasm of
infected cells (gray) compared to that of uninfected cells (white).
FIGURE 5 Integrated time histograms of the duration of binding events of
individual vRNPs to the nuclear envelope. (A) The number of vRNP binding
events with disassociation times shorter than the time indicated on the
horizontal axis. The binding times were determined from movies taken at 10
fps (0.1-s time resolution) on 13 cells. The solid line is the best-ﬁt single
exponential decay with a time constant t ¼ 2.2 s and the shaded line is the
best-ﬁt double exponential decay with two time constants t1 ¼ 1.1 s and
t2 ¼ 5.8 s. The second time constant is probably shorter than the actual
dissociation time constant due to the ﬁnite observation window (20 s). (B)
Integrated time histograms of the binding events of vRNPs to the nuclear
envelope determined from movies taken at 1 fps (1-s time resolution) on six
cells. The solid line is the best-ﬁt single exponential decay (t ¼ 24 s), and
the shaded line is the best-ﬁt double exponential decay (t1¼ 10.4 s and t2¼
113 s). Again the second time constant is probably not accurately determined
due to the ﬁnite observation window (200 s). (C) Integrated time histograms
of the binding events determined from movies taken at 0.2 fps (5-s time
resolution) on eight cells. The solid line is the best-ﬁt single exponential
decay (t ¼ 89 s). These three experiments combined suggest the presence of
three dissociation time constants, 1 s, 10 s, and 89 s.
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in investigations of gene trafﬁcking in viral infection and
gene delivery technologies. The physical and time trajecto-
ries of single genetic particles, the direct visualization of
interactions between these particles and cellular machinery,
and the transient dynamic information revealed by the time
trajectories can provide critical insights, complementary to
ensemble measurement results, into the molecular mecha-
nisms underlying the trafﬁcking of genetic materials in cells.
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